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Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard 
treatments in this cancer increase survival but do not lead to complete recovery of the patient. 
The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian 
patients with metastatic pancreatic cancer (MPC).
Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival 
(OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combination 
with gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety, 
progression-free survival (PFS), overall response rate and reduction in pain were secondary 
end points.
Results: The median OS was 8 months, and the median PFS was 5 months. A considerable 
difference in CA 19-9 before and after treatment was observed. Descriptive and correlation 
analyses were done to examine the relationship between CA 19-9 response and OS. Linear 
regression analysis between OS and CA 19-9 response revealed that CA 19-9 is an important 
predictor of OS, showing a positive correlation.
Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected by 
MPC. The drug showed an improved tolerability profile, significant pain relief and an increase 
in survival rate.
Keywords: Abraxane, chemotherapy, pancreatic carcinoma, metastasis, CA 19-9, pain, overall 
survival
Introduction
Pancreatic cancer (PA) is the fifth leading cause of death in Europe for cancer-related 
reasons, with 80% of patients ineligible for potential curative resection at diagnosis. 
In these cases, PA is diagnosed in a locally advanced stage or is metastatic with a 
particularly poor prognosis1 and a total survival rate 6% at 5 years.2,3 Treatment with 
the long-term standard care, gemcitabine (Gem) monotherapy, led to a median overall 
survival (OS) of ~5–7 months in multiple Phase III trials of patients with metastatic 
pancreatic cancer (MPC).4 Gemcitabine in association with oxaliplatin (GEMOX) 
has demonstrated discrete efficacy in metastatic or locally advanced cancer with a 
median duration of 4.5 months response with a significant neurological toxicity due to 
oxaliplatin.5 In 2011, Conroy et al6 published the results of a Phase II/III study that dem-
onstrated greater efficacy of Gem in MPC patients, highlighting a clinically meaningful 
survival benefit and better quality of life for a regimen composed of 5-fluorouracil, 
folinic acid (leucovorin), irinotecan and oxaliplatin (FOLFIRINOX) at the expense of 
increased toxicity. Recent combinations of chemotherapy and target therapy such as 
erlotinib plus Gem have achieved a significant, albeit modest, increase in OS vs Gem 
in a global study of locally advanced or MPC patients.7 The phase III trial, Metastatic 
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Pancreatic Adenocarcinoma Clinical Trial (MPACT), showed 
improved efficacy of Abraxane® (nab-paclitaxel; Celgene, 
Boudry, Switzerland) plus Gem compared to Gem alone. An 
updated OS analysis showed a 2-month difference in the arm 
with nab-paclitaxel plus Gem vs Gem alone (median, 8.7 vs 
6.6 months) and a total reduction in the risk of death of 28%, 
an improvement in survival at 1 year of 59% and an improve-
ment in survival rates at 2 years of 12%. A statistically 
significant improvement in progression-free survival (PFS) 
was noted for patients treated with nab-paclitaxel plus Gem 
compared to Gem alone, with a 1.8-month increase in PFS 
and overall response rate (ORR).8,9 Nab-paclitaxel is a tar-
geted chemotherapy with a targeted and more selective action 
that uses “nab” technology, nanotechnology. This technology 
uses albumin, a naturally occurring human protein almost 
in nanometric size, containing chemotherapeutic drugs that 
are then transported directly to the tumor site.10 According 
to the studies in the literature, the main purpose of this ret-
rospective study was to evaluate in our clinical reality the 
safety and efficacy of nab-paclitaxel in patients with MPC. 
In particular, OS analysis was evaluated as the primary end 
point. Secondary end points were carbohydrate antigen 19-9 
(CA 19-9) reduction, pain relief, tolerability and PFS.11,12
study design
This retrospective study was conducted to evaluate the safety 
and efficacy of nab-paclitaxel in association with Gem in the 
first-line treatment of adult patients with metastatic pancreatic 
adenocarcinoma. We retrospectively analyzed 80 patients 
with metastatic pancreatic carcinoma between June 2015 and 
June 2017 at the Medical Oncology Unit of the University 
Palermo and ARNAS Hospital Civico of Palermo. The 
study was approved by the ethics committee of Policlinico 
“P Giaccone”, Palermo, and all patients provided written 
informed consent to review their medical records. The nab-
paclitaxel was administered up to progression of the disease 
(PD) or the development of an unacceptable toxicity.
Patients and methods
Patients’ selection
We considered only patients who met the following inclusion 
criteria: 1) histologically or cytologically confirmed diagnosis 
of metastatic pancreatic adenocarcinoma; 2) performance sta-
tus 0–2 according to the Eastern Cooperative Oncology Group 
(ECOG); 3) clinical and radiological evidence of metastatic 
disease (number of lesion $1 according to the Response 
Evaluation Criteria in Solid Tumors (RECIST; v 1.1); and 
4) adequate liver, renal and blood functionality (neutrophils 
.2.0 × 109/L, platelets .100 × 109/L, hemoglobin .10 g/dL, 
creatinine ,1 mg/dL × upper limit of normal [ULN], bili-
rubin ,1 × ULN, AST and ALT ,5 × ULN). Similar to 
previous studies,13–15 we excluded patients who showed a 
hypersensitivity to nab-paclitaxel and its excipients or other 
formulation components; diagnosis of other malignancies, 
with the exception of skin basal cell carcinoma and serious 
comorbidities not adequately checked by other ongoing 
therapies (eg, liver disease, diabetes, infections, heart dis-
ease, etc.).
study assessments
evaluation of the response rate and toxicity
The response rate in terms of reduction in CA 19-9 and mea-
surable pathology (at 8 weeks after the end of treatment) was 
evaluated before the beginning of each treatment cycle and 
then every 3 months until progression of the disease. The 
spiral CT scan with and without contrast medium was always 
done before the start of each treatment cycle, then every 
3 months until disease progression and whenever an increase 
in CA 19-9 or a presumed clinical progression was reported. 
Total-body PET was done if advised by the oncologist for 
any suspicion of disease progression. For those patients who 
did not show a measurable pathology, a sustained reduction 
of $50% in serum levels of CA 19-9 was observed as treat-
ment response to baseline values. Progression of CA 19-9 was 
considered as 1) an increase in CA 19-9 $25% compared to 
baseline values in those patients who did not achieve a sig-
nificant reduction ($50%) in serum levels of CA 19-9 during 
treatment, and 2) a 50% increase in the lowest observed level in 
patients who achieved a significant reduction ($50%) in serum 
levels of CA 19-9 during treatment. The toxicity associated 
with the treatment and the side effects were evaluated after 
each course of treatment and reported according to the Cancer 
Therapy Evaluation Program, Common Terminology Criteria 
for Adverse Events (CTCAE), version 4.0.
Modality of administration
The recommended dose of nab-paclitaxel was 125 mg/m2, 
administered intravenously within 30 minutes on days 1, 8 
and 15 of each 28-day cycle. The recommended concomitant 
dose of Gem was 1,000 mg/m2 administered intravenously 
within 30 minutes immediately after completion of nab-
paclitaxel administration on days 1, 8 and 15 of each 28-day 
cycle. Patients were premedicated at least 30 minutes before 
the infusion with steroid (sodium dexamethasone phosphate), 
antiemetics, antihistamines and H2 antagonists. In addition, 
during the entire treatment period, the patient was advised 
to have adequate hydration to prevent complications such as 
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renal failure. The treatment was administered up to the PD or 
the development of an unacceptable toxicity. According to the 
clinical practice procedures, the therapy was postponed for up 
to 2 weeks if the neutrophil count was ,1.5 × 109/L, platelet 
count was ,100 × 109/L, hemoglobin level was ,8.5 g/dL or 
bilirubin and/or transaminase levels were .1.5 × ULN. In the 
case of neutropenia (G2–G3), G-CSF was also given before-
hand, subcutaneously. If major anemia of neutropenia (G2–G3), 
blood transfusions are done or in less severe cases, erythropoi-
etin vial subcutaneously, and finally for thrombocytopenia the 
steroid therapy or the platelet endovenous infusion.
statistical analyses
The normality of the distribution was checked using the 
univariate indices of skewness and kurtosis with an accep-
tance threshold equal to 1. All variables complied with 
normality indices. Descriptive statistics were useful to pro-
vide a sociodemographic representation and the distribution 
of all variables. The disease control rate was defined as the 
percentage of patients with an objective response and/or 
stable disease (SD) lasting .5 months. Inferential statistical 
analyses were performed to detect any significant relation-
ships among the considered variables. PFS and OS were 
calculated from the start date of the treatment until the date of 
disease progression or death from any cause for PFS and until 
the date of the last follow-up, death or the final follow-up day 
of the evaluation for OS. The follow-up date was June 2017. 
PFS and OS curves were estimated by using the Kaplan–
Meier method. To calculate the sample size, a reduction in 
CA 19-9 of at least 25% from baseline was considered to be 
clinically relevant, with an α error of 5% and a statistical 
power of 80%, as reported in the literature. The relationship 
between OS and CA 19-9 was analyzed by linear regression 
(OS was the dependent variable Y, and the CA 19-9 response 
was the independent variable X). The goodness of fit was 
assessed with the coefficient of determination R2, which rep-
resents the variability proportion between the observed values 
for Y, as explained by the linear regression of Y over X. The 
slope values could be interpreted as an increase in Y at every 
increase in X values. Data were represented via a scatter plot 
and regression line. A p-value threshold of 0.05 was used 
to evaluate the significance of the obtained data. Statistical 
analysis was performed using the Statistical Package for the 
Social Sciences (SPSS) software, version 22.0.
Results
Treatment exposure and follow-up
Demographic, clinical and pathological features of 80 patients 
with MPC are reported in Table 1. At the time of diagnosis, 
patients were aged between 48 and 75 years, with a mean age 
of 62 years. The response rate of CA 19-9 in 8 weeks, after the 
end of treatment, was 55%. Treatment with nab-paclitaxel 
in combination with Gem was well tolerated and gave 
a good level of disease control (partial response [PR] 
+ SD, 55%). After an average 6-month follow-up dura-
tion (range 3–8 months), 18 (22.5%) patients had a PR 
to therapy, 26 (32.5%) patients had an SD and 36 (45%) 
patients had PD.
CA 19-9 reduction
In our cohort of patients, we found a significant impact using 
nab-paclitaxel plus Gem on CA 19-9 reduction (.50%). In 
particular, the mean reduction was 55% (95% CI: 38.67–
54.63) and was consistent with data already published. This 
reduction was related to a better survival (Figure 1). Linear 
regression analysis between OS and CA 19-9 response 
revealed that CA 19-9 is an important predictor of OS, show-
ing a positive correlation with OS (β = 0.365, p , 0.01). The 
explained variance, in this analysis, was 55% (R2 = 0.60) with 
a slope of 1.46 (p = 0.0032; Figure 1). The Bravais–Pearson 
index showed a positive correlation between the response rate 
of CA 19-9 and OS, with a value of 0.60 (95% CI: 0.25–0.87; 
p = 0.003; Table 2).
Os analysis
Among 80 patients enrolled in this study, updated interim 
analysis of survival (until the last follow-up in June 2017) 
Table 1 Baseline demographic and clinical characteristics (n = 80)
Characteristics Patients n (%)
Mean age (range), years 62 (48–75)
sex
Male 42 (52)
Female 38 (48)
ecOg performance status
0 8 (10)
1 38 (47.5)
2 34 (42.5)
Median CA 19-9 level (range), ng/mL, ,59 cutoff 150 (80–1,200)
Primary tumor location
head 34 (42)
Body 23 (28)
Tail 8 (10)
Metastatic site
liver 58 (72.5)
lung 19 (24)
Peritoneum 8 (10)
Biliary stent 22 (27.5)
Previous Whipple procedure 8 (10)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbo-
hydrate antigen 19-9.
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showed a median OS of 8 months (95% CI: 7.13–8.86; 
Figure 2).
Time of PFs analysis
In this study, median duration of response was 5 months 
(95% CI: 3.86–6.13), while median time of progression in 
patients with PR or SD was 5.13 months (95% CI: 4.13–6.14; 
Figure 3).
Tolerability
In the group of patients, nab-paclitaxel plus Gem treatment 
were well tolerated. Treatment-related toxicity was not signif-
icant, and the side effects were evaluated after each course of 
therapy and reported in accordance with the Cancer Therapy 
Evaluation Program, CTCAE, version 4.0. The most common 
adverse events were G1–G2 anemia that required the use of 
erythropoietin subcutaneously, G1–G2 neutropenia, a few G3 
cases requiring the use of G-CSF, grades G1–G2 thrombocy-
topenia corrected with the use of corticosteroids and finally 
alopecia that occurred in 15% of patients. Events associated 
with the treatment of toxicity and side effects are described 
in Tables 3 and 4, respectively. No patient had treatment 
interrupted due to severe side effects, but adverse events of 
grade $3 were effectively treated with dose reductions and 
delays (Tables 3 and 4).
response to pain
Pain reduction assessed by the visual analog scale (VAS) showed 
a response to pain in 34% of patients. In addition, improvement 
Figure 1 Regression analysis between CA 19-9 response and OS of patients (N = 80).
Abbreviations: CA 19-9, carbohydrate antigen 19-9; OS, overall survival.
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Table 2 Pearson’s correlation among CA 19-9 and OS in the 
treatment with Abraxane® (nab-paclitaxel; Celgene, Boudry, 
switzerland; n = 80)
Variable CA 19-9 OS
CA 19-9 1 0.60**
Os 0.60** 1
Notes: **p , 0.01. Bold figures indicate the significance index of the relation 
between variables.
Abbreviations: CA 19-9, carbohydrate antigen 19-9; OS, overall survival.
Figure 2 Kaplan–Meier plot of mOs (interim analysis; n = 80).
Abbreviations: mOs, median overall survival; Os, overall survival.
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Figure 3 Kaplan–Meier plot of mPFs (interim analysis; n = 80).
Abbreviations: mPFS, median progression-free survival; PFS, progression-free 
survival.
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in quality of life was identified with a reduction in pain 
symptoms in 58.3% of patients with a VAS score of ,22 points 
and a reduced use of analgesics in 48% of patients.
Discussion
In Western countries, PA is one of the most frequent cancers 
with a high mortality rate. This study aims to evaluate the 
efficacy of the combination of a new chemotherapy-targeted 
drug nab-paclitaxel in association with Gem in Italian patients 
with metastatic pancreatic adenocarcinoma, as the first line 
of treatment.16 Our findings are consistent with a recent and 
up-to-date analysis of the survival data of the study MPACT, 
a Phase III study comparing nab-paclitaxel plus Gem with 
monotherapy based on Gem alone. In the MPACT trial, nab-
paclitaxel plus Gem demonstrated a longer OS (median, 8.5 
vs 6.7 months; hazard ratio [HR], 0.72; 95% CI: 0.62–0.83; 
p , 0.001).17 Our analysis shows that treatment was well 
tolerated and was associated with an increase in OS and PFS 
with a good overall response rate (ORR) and a reduction in 
CA 19-9 levels. In particular, CA 19-9 reduction was .50%, 
and we also demonstrated that this reduction was linked to an 
increase in the OS. Therefore, the CA 19-9 response may be 
an important predictor of an increase in OS with a positive 
correlation obtained between the CA 19-9 response and OS 
(β = 0.365, p , 0.01). However, our findings are in line with 
those reported in the literature, with an OS of 8 months (95% 
CI: 7.13–8.86) and a PFS of 5 months (95% CI: 3.86–6.13); 
this work has a limit that must be taken into account, for 
example, the small sample size. Nevertheless, we can state 
that in the first line of treatment of MPC, nab-paclitaxel 
plus Gem therapy is a valid therapeutic option that can be 
considered standard. The treatment shown an improvement 
in the quality of life with a reduction in pain.18,19 In addi-
tion, the treatment showed a good safety and tolerability 
profile; neutropenia was the most frequent side-effect asso-
ciated with treatment, and only 14% of patients developed 
severe neutropenia (CTCAE grade 3) treated with G-CSF. 
This result is in accordance with published data (Studio 
MPACT) showing a greater risk of mild to moderate side 
effects associated with the treatment.9,20 In 2017, McBride 
et al compared patients treated with nab-paclitaxel plus 
Gem vs FOLFIRINOX. The authors demonstrated that 
the two treatments had a similar duration but lower costs 
of outpatient prescriptions, treatment administration and 
supportive care in nab-paclitaxel plus Gem.18 These data 
indicate that nab-paclitaxel plus Gem has a manage-
able safety profile and is an effective first-line option in 
patients in Western Europe with MPC.21–23
Nab-paclitaxel is a target therapy with nanotechnology, 
which allows transporting the drug at optimal concentrations 
directly to the tumor lesion; furthermore, nab-paclitaxel shows 
a good efficacy and safety profile. Considering other fluoro-
based (FOLFIRINOX) schema therapies, nab-paclitaxel 
showed minor toxicity and more safety in fragile and 
comorbid patients.24 Prospective studies and cohort studies 
have demonstrated that therapy with nab-paclitaxel, directly 
or indirectly compared with other Gem-based, platinum 
derivative and fluorine-based (FOLFIRINOX) therapies, 
has greater efficacy and lower toxicity in the setting of 
patients who frequently have peritoneal metastasis and 
biliary stand.25,26 Finally, use of nab-paclitaxel in the first 
line of treatment, as suggested in the guidelines, allows per-
formance of a second line of treatment with other drugs.27
Conclusion
Our findings, even though with a limited number of patients, 
are consistent with clinical evidence reported in the literature. 
The combination of the two drugs nab-paclitaxel plus 
Gem was effective, well tolerated and safe in patients with 
metastatic pancreatic adenocarcinoma, and the toxicity 
associated with the treatment is acceptable.28,29 Additionally, 
Table 3 Treatment-associated toxicity (N = 80)
Adverse events of any grade No of patients (%)
hematologic 38 (47.5)
neurologic 10 (12.5)
gastrointestinal 21 (26)
infections 6 (7)
Metabolic 13 (16)
Flu-like symptoms 7 (8)
cardiovascular 2 (2.5)
Table 4 adverse events graded according to cTcae, version 
4.0 (n = 80)
Adverse event No of patients (%)
hematological
grades 2–3 anemia 15 (8)
grades 1–2 neutropenia 23 (28)
grade 3 neutropenia 11 (14)
Grade 3 thrombocytopenia 10 (12.5)
Febrile neutropenia 5 (6)
Leukopenia 10 (12.5)
Non-hematological
grade 3 asthenia 27 (33.7)
grades 2–3 peripheral neuropathy 18 (22.5)
grade 3 stomatitis 8 (10)
grade 2 alopecia 13 (15)
grades 2–3 diarrhea 9 (11)
Abbreviation: cTcae, common Terminology criteria for adverse events.
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more than half of the patients being treated with PD received 
a subsequent therapy, indicating that nab-paclitaxel plus Gem 
was also a feasible first-line option on which it is possible to 
build a treatment plan. Pain response rates and quality of life 
are satisfactory.30 Based on these findings, we can conclude 
that treatment with nab-paclitaxel plus Gem is a valuable 
therapeutic regimen for the progressive form of MPC.
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